Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Saw palmetto claim

This article was originally published in The Tan Sheet

Executive Summary

Petition for rehearing en banc denied for supplement marketers seeking a health claim linking saw palmetto to benign prostatic hyperplasia. The petition was filed on behalf of the plaintiffs by Washington, D.C. law firm Emord & Associates Feb. 19 (1"The Tan Sheet" March 1, 2004, p. 15). Julian Whitaker, MD, the American Association for Health Freedom, Pure Encapsulations, Durk Pearson and Sandy Shaw plan to petition for a writ of certiorari to the Supreme Court before June 7...

You may also be interested in...



Saw Palmetto En Banc Appeals Court Re-Hearing Requested

A group of supplement marketers seeking approval of a health claim linking saw palmetto to treatment of benign prostatic hyperplasia have filed a petition for an en banc rehearing with the U.S. Court of Appeals

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail

Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.

Topics

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel